OBJECTIVE: Conflicting results have been reported about activated leukocyte cell adhesion molecule (ALCAM) expression in breast cancer and its prognostic value. Little is known about the role of ALCAM levels in the serum of breast cancer patients. METHODS: We analyzed soluble ALCAM (sALCAM) levels in the serum of 157 primary breast cancer patients and 48 healthy women by ELISA. In addition, we determined ALCAM protein expression by Western blot analysis (n = 120) and mRNA expression by cDNA microarray analysis (n = 115) in the tumor tissue of corresponding patients. RESULTS: sALCAM levels differed between patients and healthy controls (median 24.2 vs. 18.9 ng/ml, p < 0.001). We observed no correlation between serum levels and protein or mRNA expression in corresponding tumors (r < 0.1, p = n.s.). sALCAM levels were not correlated with histological type, grading, tumor stage, or patient age, but elevated sALCAM levels were associated with shorter disease-free survival (HR = 1.97, 95% CI 1.01-3.2, p = 0.043). CONCLUSIONS: Our results indicate that sALCAM can be detected in the serum of patients with primary breast cancer. Elevated serum levels might indicate more aggressive tumor behavior as they might be an independent factor for a worse prognosis in breast cancer patients.
OBJECTIVE: Conflicting results have been reported about activated leukocyte cell adhesion molecule (ALCAM) expression in breast cancer and its prognostic value. Little is known about the role of ALCAM levels in the serum of breast cancerpatients. METHODS: We analyzed soluble ALCAM (sALCAM) levels in the serum of 157 primary breast cancerpatients and 48 healthy women by ELISA. In addition, we determined ALCAM protein expression by Western blot analysis (n = 120) and mRNA expression by cDNA microarray analysis (n = 115) in the tumor tissue of corresponding patients. RESULTS: sALCAM levels differed between patients and healthy controls (median 24.2 vs. 18.9 ng/ml, p < 0.001). We observed no correlation between serum levels and protein or mRNA expression in corresponding tumors (r < 0.1, p = n.s.). sALCAM levels were not correlated with histological type, grading, tumor stage, or patient age, but elevated sALCAM levels were associated with shorter disease-free survival (HR = 1.97, 95% CI 1.01-3.2, p = 0.043). CONCLUSIONS: Our results indicate that sALCAM can be detected in the serum of patients with primary breast cancer. Elevated serum levels might indicate more aggressive tumor behavior as they might be an independent factor for a worse prognosis in breast cancerpatients.
Authors: Amanda G Hansen; Tanner J Freeman; Shanna A Arnold; Alina Starchenko; Celestial R Jones-Paris; Michael A Gilger; Mary K Washington; Kang-Hsien Fan; Yu Shyr; Robert D Beauchamp; Andries Zijlstra Journal: Cancer Res Date: 2013-03-28 Impact factor: 12.701
Authors: Amanda G Hansen; Shanna A Arnold; Ming Jiang; Trenis D Palmer; Tatiana Ketova; Alyssa Merkel; Michael Pickup; Susan Samaras; Yu Shyr; Harold L Moses; Simon W Hayward; Julie A Sterling; Andries Zijlstra Journal: Cancer Res Date: 2014-01-02 Impact factor: 12.701
Authors: Alba Sulaj; Johanna Zemva; Ulrike Zech; Annika Woehning; Maik Brune; Gottfried Rudofsky; Peter P Nawroth; Thomas Fleming; Rüdiger von Bauer Journal: BMC Endocr Disord Date: 2016-10-13 Impact factor: 2.763
Authors: Shanna A Arnold Egloff; Liping Du; Holli A Loomans; Alina Starchenko; Pei-Fang Su; Tatiana Ketova; Paul B Knoll; Jifeng Wang; Ahmed Q Haddad; Oluwole Fadare; Justin M Cates; Yair Lotan; Yu Shyr; Peter E Clark; Andries Zijlstra Journal: Oncotarget Date: 2017-01-03
Authors: Jaume Reventos; Antonio Gil-Moreno; Eva Colas; Laura Devis; Elena Martinez-Garcia; Cristian P Moiola; Maria Teresa Quiles; Maria Antonia Arbos; Tomita Vasilica Stirbat; Françoise Brochard-Wyart; Ángel García; Lorena Alonso-Alconada; Miguel Abal; Berta Diaz-Feijoo; William Thomas; Sylvie Dufour; Gemma Mancebo; Francesc Alameda Journal: Oncotarget Date: 2018-03-30
Authors: Andrew J Sanders; Sioned Owen; Liam D Morgan; Fiona Ruge; Ross J Collins; Lin Ye; Malcolm D Mason; Wen G Jiang Journal: Oncotarget Date: 2019-10-29